News & Updates

Among people with nonalcoholic fatty liver disease (NAFLD), those who are lean appear to be at higher risk of death than their overweight and obese counterparts despite having fewer metabolic comorbidities, a study has shown.

The addition of the antipsychotic drug aripiprazole to current antidepressant medications may help improve the symptoms of clinical depression in older adults who have not responded to standard treatments, as reported in a study.

Use of the Erbium-doped yttrium-aluminum-garnet (Erbium YAG) laser in postmenopausal women appears to improve symptoms of overactive bladder (OAB) and vaginal atrophy, as shown in a study.

Among prostate cancer patients, those without obesity are more likely to experience earlier recovery in urinary function after radical prostatectomy and have better sexual function both before and after the procedure, as reported in a study.

Encouraging people to check their blood pressure (BP) regularly and boost adherence to antihypertensive medications can potentially reduce stroke mortality and morbidity, suggests a study. Improving the literacy level and reducing the smoking rate may help achieve these goals.

Use of antihypertensive agents that modify the renin-angiotensin system (RAS) helps lower the risk of cardiovascular disease (CVD) in patients with systemic lupus erythematosus (SLE), suggests a study.

In patients with metastatic castration-sensitive prostate cancer, triplet therapy may be ideal for fit patients with synchronous (de novo) high-volume disease while the androgen pathway inhibitor (API) doublet combinations may be preferred for those with metachronous (recurrent) low-volume disease, according to the results of a meta-analysis.

Triplet therapy with darolutamide, androgen-deprivation therapy (ADT) and docetaxel improves overall survival (OS) by approximately 30 percent vs ADT plus docetaxel in most disease volume and risk subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC), a post hoc analysis of the phase III ARASENS trial has shown.